Obila 20 tablet: Each tablet contains Bilastine INN 20 mg.
Obila 10 ODT: Each oral dispersible tablet contains Bilastine INN 10 mg.
Obila syrup: Each 5 mL contains Bilastine INN 12.5 mg.
Obila is a preparation of bilastine which is a non-sedating, long acting histamine antagonist with selective peripheral H 1 receptor antagonist affinity and no affinity for muscarinic receptors. Bilastine inhibits histamine induced skin reactions for 24 hours.
Route of administration : Obila should be administered in oral route one hour before or two hours after intake of food. The recommended dose in adults, including the elderly and adolescents aged 12 years and over is one Obila 20 tablet once daily.
The recommended dose in children between 6 to 11 years of age with a body weight of at least 20 kg is 10 mg bilastine once daily (one Obila 10 ODT once daily or Obila syrup 4 mL once daily) limited to the period of exposure to allergens.
Ketoconazole, erythromycin, or diltiazem co-administration in patients with moderate-to-severe renal impairment increases bilastine exposure; grapefruit juice reduces bilastine bioavailability by 30%.
It is contraindicated in patients with known hypersensitivity to bilastine or any other components of this product.
Common: Headache, drowsiness, rhinitis, allergic conjunctivitis, abdominal pain.
Overdose
In the event of overdose, general supportive measures and proper monitoring should be initiated.
Category B. Inadequate well-controlled studies in pregnant women; use only if clearly indicated. Lactation: Excretion in breast milk unknown; evaluate maternal need against infant risks.
Store below 30°C in a cool, dry place. Protect from light and moisture. Keep out of reach of children.